Market Trends Incyte stock tumbles despite meeting main goal in skin disease treatment trial (INCY:NASDAQ)By admin8996erT0allMarch 17, 2025 AlexanderFord/E+ via Getty ImagesIncyte (NASDAQ:INCY) shares fell after the company announced late-stage trial results of povorcitinib to treat hidradenitis suppurativa,…
Market Trends Incyte, Syndax get FDA okay for 9 mg, 22 mg Niktimvo vialsBy admin8996erT0allJanuary 15, 2025 Olivier Le MoalIncyte (NASDAQ:INCY) and Syndax Pharmaceuticals (SNDX) have received FDA approval for their drug Niktimvo in 9 mg and…
